NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Drug Patent Profile
✉ Email this page to a colleague
When do Norepinephrine Bitartrate In 5% Dextrose patents expire, and when can generic versions of Norepinephrine Bitartrate In 5% Dextrose launch?
Norepinephrine Bitartrate In 5% Dextrose is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.
The generic ingredient in NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is norepinephrine bitartrate. There are five drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 5% Dextrose
A generic version of NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE was approved as norepinephrine bitartrate by MEITHEAL on March 3rd, 2003.
Summary for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 8 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE at DailyMed |
Recent Clinical Trials for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tunis University | Phase 4 |
Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
Wright State University | Phase 3 |
See all NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE clinical trials
Pharmacology for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
Drug Class | Catecholamine |
Anatomical Therapeutic Chemical (ATC) Classes for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare Corp | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214313-001 | Jan 15, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Baxter Hlthcare Corp | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214313-002 | Jan 15, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Baxter Hlthcare Corp | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214313-003 | Nov 21, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |